Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis
- PMID: 35256568
- DOI: 10.1097/LGT.0000000000000661
Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis
Conflict of interest statement
The authors have declared they have no conflicts of interest.
References
-
- Syed YY. Ocrelizumab: a review in multiple sclerosis. CNS Drugs 2018;32:883–90.
-
- Selva-Nayagam P, Fischer G, Hamann I, et al. Rituximab causing deep ulcerative suppurative vaginitis/pyoderma gangrenosum. Curr Infect Dis Rep 2015;17:478.
-
- Sanchez IM, Lowenstein S, Johnson KA, et al. Clinical features of neutrophilic dermatosis variants resembling necrotizing fasciitis. JAMA Dermatol 2019;155:79–84.
-
- Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol 2018;154:461–6.
-
- Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol 2015;73:691–8.